ACE 083

Drug Profile

ACE 083

Alternative Names: ACE-083

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acceleron Pharma
  • Class Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Charcot-Marie-Tooth disease; Facioscapulohumeral muscular dystrophy
  • Discontinued Inclusion body myositis

Most Recent Events

  • 17 Nov 2017 Discontinued - Preclinical for Inclusion body myositis in USA (IM)
  • 25 Apr 2017 Phase-II clinical trials in Charcot-Marie-Tooth disease (In adults, In the elderly) in USA (IM) (NCT03124459)
  • 16 Mar 2017 Acceleron plans a phase II trial in Charcot-Marie-Tooth disease (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top